52 results about "Apolipoprotein B" patented technology

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

The invention discloses a construction method of a gene detection library of familial hypercholesterolemia and a gene detection kit and relates to gene mutation of LDLR (Low-Density Lipoprotein Receptor), APOB (Apolipoprotein B) and PCSK9 (Proprotein Convertase Subtilisin / Kexin type 9). In order to ensure that all target regions (including an entire coding region and an alternative splicing regionof a gene to be detected) are covered and prevent a primer dimer or a short segment from being formed between primers of adjacent amplicons, a PCR (Polymerase Chain Reaction) amplification primer isdivided into two independent primer pools; then primer sequence digestion, sequencing connector connection, library purification and quality detection are carried out; finally, the detection library is constructed. The method has the advantages that library establishment steps are simple and rapid, the cost is effectively reduced, the working amount is reduced, variation types are comprehensive, the detection accuracy reaches 100 percent and the flux is high.

An assay for testing a subject for diabetes or a predisposition to diabetes including analyzing a biological fluid from a subject for the presence of one or more proteins selected from the group consisting of Alpha 2 macroglobulin, Apolipoprotein AII, Immunoglobulin alpha heavy chain constant region, Immunoglobulin mu chain C region, Chain A of Human IgA1, Inter-alpha-trypsin inhibitor heavy chain H4 precursor, and Apolipoprotein B11; wherein detection of the protein is indicative of diabetes or a predisposition to diabetes in the subject.

Compositions and regimens useful in reducing one or more of: LDL-cholesterol, total cholesterol, and / or fasting triglycerides in a subject, and / or modifying fractional catabolic rate (FCR) of LDL apolipoprotein B (apoB) from baseline to a selected time point after rAAV administration are provided. The method involves administering to the human subject via a peripheral vein by infusion of a suspension of replication deficient recombinant adeno-associated virus (rAAV).

A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z- dependent protease inhibitor and plasma serine protease inhibitor.